Lloyd A Gall

Array ( [id] => 16571019 [patent_doc_number] => 20210010025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP [patent_app_type] => utility [patent_app_number] => 16/810422 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453251 [patent_doc_number] => 11268097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability [patent_app_type] => utility [patent_app_number] => 16/808611 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 8 [patent_no_of_words] => 14546 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468218 [patent_doc_number] => 20200369755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => ANTIBODIES RECOGNIZING TAU [patent_app_type] => utility [patent_app_number] => 16/808209 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283760 [patent_doc_number] => 20200277362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Humanized Antibodies That Recognize Alpha-Synuclein [patent_app_type] => utility [patent_app_number] => 16/795479 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16093563 [patent_doc_number] => 20200200768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS [patent_app_type] => utility [patent_app_number] => 16/791984 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361024 [patent_doc_number] => 20200317775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => SP35 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/789738 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650004 [patent_doc_number] => 10927167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Anti-complement factor C1Q antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/784020 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 35321 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525272 [patent_doc_number] => 20200399352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/782654 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960549 [patent_doc_number] => 20200164026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => Intranasal Delivery of Cell Permeant Therapeutics [patent_app_type] => utility [patent_app_number] => 16/738542 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312396 [patent_doc_number] => 20200291134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/712525 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963213 [patent_doc_number] => 20200165358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF SYNUCLEINOPATHIES [patent_app_type] => utility [patent_app_number] => 16/692382 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831949 [patent_doc_number] => 20200131256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => ANTI-PACAP ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/692236 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17330227 [patent_doc_number] => 11220680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-11 [patent_title] => Polypeptide for treating pathological blood clots [patent_app_type] => utility [patent_app_number] => 16/691578 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 33 [patent_no_of_words] => 13346 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16691578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553951 [patent_doc_number] => 20200061387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => OPTOGENETIC THERAPEUTIC AND METHOD OF TREATING RETINAL DEGENERATIVE AND NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/672899 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605975 [patent_doc_number] => 10906967 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Anti-transthyretin antibodies [patent_app_type] => utility [patent_app_number] => 16/669375 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 58 [patent_no_of_words] => 29317 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468857 [patent_doc_number] => 20230203140 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-06-29 [patent_title] => HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/282592 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468857 [patent_doc_number] => 20230203140 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-06-29 [patent_title] => HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/282592 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16284756 [patent_doc_number] => 20200278358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/588481 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20901 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16588481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649713 [patent_doc_number] => 20200087386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/584634 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681287 [patent_doc_number] => 20200095307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA [patent_app_type] => utility [patent_app_number] => 16/577703 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16577703 [rel_patent_id] =>[rel_patent_doc_number] =>)